UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 87.

Noguera-Julian, M; Cozzi-Lepri, A; Di Giallonardo, F; Schuurman, R; Däumer, M; Aitken, S; Ceccherini-Silberstein, F; D'Arminio Monforte, A; Geretti, A M; Booth, C L; Kaiser, R; Michalik, C; Jansen, K; Masquelier, B; Bellecave, P; Kouyos, R D; Castro, E; Furrer, H; Schultze, A; Günthard, H F; Brun-Vezinet, F; Metzner, K J; Paredes, R (2016). Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical Microbiology and Infection, 22(2):191-200.

Schaerer, V; Haubitz, S; Kovari, H; Ledergerber, B; Ambrosioni, J; Cavassini, M; Stoeckle, M; Schmid, P; Decosterd, L; Aouri, M; Böni, J; Günthard, H F; Furrer, H; Metzner, K J; Fehr, J; Rauch, A (2015). Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV Medicine, 16(10):599-607.

Schäfer, J; Young, J; Bernasconi, E; Ledergerber, B; Nicca, D; Calmy, A; Cavassini, M; Furrer, H; Battegay, M; Bucher, H C; Swiss HIV Cohort Study (2015). Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 16(1):3-14.

Letang, E; Muller, M C; Ntamatungiro, A J; Kimera, N; Faini, D; Furrer, H; Battegay, M; Tanner, M; Hatz, Christoph; Boulware, D R; Glass, T R (2015). Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. Open Forum Infectious Diseases, 2(2):ofv046.

Metzner, K J; Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, H; Hirsch, H; Vernazza, P L; Cavassini, M; Calmy, A; Bernasconi, E; Weber, R; Gunthard, H F (2014). Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. AIDS, 28(15):2231-2239.

Hasse, B; Iff, M; Ledergerber, B; Calmy, A; Schmid, P; Hauser, C; Cavassini, M; Bernasconi, E; Marzolini, C; Tarr, P E; Aubert, V; Barth, J; Battegay, M; Bernasconi, E; Boni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Egger, M; Elzi, L; Fehr, J; Fellay, J; Furrer, H; Fux, C A; Gorgievski, M; Gunthard, H; Haerry, D; Hasse, B; Hirsch, H H; Hosli, I; Kahlert, C; Kaiser, L; Keiser, O; Klimkait, T; Kouyos, R; Kovari, H; Ledergerber, B; Martinetti, G; Martinez de Tejada, B; Metzner, K; Muller, N; Nadal, D; Pantaleo, G; Rauch, A; Regenass, S; Rickenbach, M; Rudin, C; Schoni-Affolter, F; Schmid, P; Schultze, D; Schupbach, J; Speck, R; Staehelin, C; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2014). Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV cohort study. Open Forum Infectious Diseases, 1(2):ofu040.

Young, J; Wang, Q; Fux, C A; Bernasconi, E; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Weber, R; Battegay, M; Bucher, H C (2014). The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Medicine, 15(8):505-510.

Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, H; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Schmid, P; Schultze, D; Schöni-Affolter, F; Schüpbach, J; Speck, R; Taffé, P; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2013). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Medicine, 14(4):195-207.

Furrer, H (2013). Dinosaurierspuren, Korallen und andere Fossilien - Zeugen einer langen geologischen Geschichte. In: Haller, H; Eisenhut, A; Haller, R. Atlas des Schweizerischen Nationalparks: Die ersten 100 Jahre. Bern: Hauptverlag, 44-45.

Furrer, H; Schlüchter, C; Inderbitzin, L; Pointner, E; Margreth, A; Gaar, D (2013). Geologie und Erdgeschichte: lihtologisches und zeitliches Fundament des SNP. In: Haller, H; Eisenhut, A; Haller, R. Atlas des Schweizerischen Nationalparks: Die ersten 100 Jahre. Bern: Hauptverlag, 16-17.

Beardmore, S R; Orr, P J; Manzocchi, T; Furrer, H; Johnson, C (2012). Death, decay and disarticulation: Modelling the skeletal taphonomy of marine reptiles demonstrated using Serpianosaurus (Reptilia; Sauropterygia). Palaeogeography, Palaeoclimatology, Palaeoecology, 337-338:1-13.

Dehnert, A; Lowick, S E; Preusser, F; Anselmetti, F S; Drescher-Schneider, R; Graf, H R; Heller, F; Horstmeyer, H; Kemna, H A; Nowaczyk, N R; Züger, A; Furrer, H (2012). Evolution of an overdeepened trough in the northern Alpine Foreland at Niederweningen, Switzerland. Quaternary Science Reviews, 34:127-145.

Beardmore, S R; Orr, P J; Manzocchi, T; Furrer, H (2012). Float or sink: modelling the taphonomic pathway of marine crocodiles (Mesoeucrocodylia, Thalattosuchia) during the death–burial interval. Palaeobiodiversity and palaeoenvironments, 92(1):83-98.

von Wyl, V; Yerly, S; Böni, J; Shah, C; Cellerai, C; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Ledergerber, B; Günthard, H F (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clinical Infectious Diseases, 54(1):131-140.

Froitzheim, N; Weber, S; Nagel, T J; Ibele, T; Furrer, H (2012). Late Cretaceous extension overprinting a steep belt in the Northern Calcareous Alps (Schesaplana, Rätikon, Switzerland and Austria). International Journal of Earth Sciences, 101(5):1315-1329.

Vrouenraets, S M E; Wit, F W N M; Garcia, E Fernandez; Huber, M; Brinkman, K; Moyle, G; Domingo, P; Tarr, P E; Podzamczer, D; Ristola, M; Gatell, J M; Livrozet, J M; Furrer, H; Reiss, P (2012). Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clinical Trials, 13(2):103-110.

Staehelin, C; Keiser, O; Calmy, A; Weber, R; Elzi, L; Cavassini, M; Schmid, P; Bernasconi, E; Furrer, H (2012). Longer term clinical and virological outcome of Sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 59(1):79-85.

Fenner, L; Gagneux, S; Helbling, P; Battegay, M; Rieder, H L; Pfyffer, G E; Zwahlen, M; Furrer, H; Siegrist, H H; Fehr, J; Dolina, M; Calmy, A; Stucki, D; Jaton, K; Janssens, J P; Stalder, J M; Bodmer, T; Ninet, B; Böttger, E C; Egger, M (2012). Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: Role of immigration and HIV infection. Journal of Clinical Microbiology, 50(2):388-395.

Thierfelder, C; Weber, R; Elzi, L; Furrer, H; Cavassini, M; Calmy, A; Bernasconi, E; Gutmann, C; Ledergerber, B (2012). Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. HIV Medicine, 13(2):118-126.

Scheyer, T M; Neenan, J M; Renesto, S; Saller, F; Hagdorn, H; Furrer, H; Rieppel, O; Tintori, A (2012). Revised paleoecology of placodonts – with a comment on ‘The shallow marine placodont Cyamodus of the central European Germanic Basin: its evolution, paleobiogeography and paleoecology’ by C.G. Diedrich. Historical biology, 24(3):257-267.

Furrer, H (2011). Neue Fossilien aus dem Hochgebirge Graubündens. Schweizer Strahler, 45(2):29-33.

Wandeler, G; Keiser, O; Hirschel, B; Günthard, H F; Bernasconi, E; Battegay, M; Clerc, O; Vernazza, P L; Furrer, H (2011). A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS ONE, 6(12):e27903.

Marzolini, C; Back, D; Weber, R; Furrer, H; Cavassini, M; Calmy, A; Vernazza, P; Bernasconi, E; Khoo, S; Battegay, M; Elzi, L (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9):2107-2111.

Lubomirov, R; Colombo, S; di Iulio, J; Ledergerber, B; Martinez, R; Cavassini, M; Hirschel, B; Bernasconi, E; Elzi, L; Vernazza, P; Furrer, H; Günthard, H F; Telenti, A (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. Journal of Infectious Diseases, 203(2):246-257.

El Amari, E B; Combescure, C; Yerly, S; Calmy, A; Kaiser, L; Hasse, B; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2011). Clinical relevance of cytomegalovirus viraemia(*,†). HIV Medicine, 12(7):394-402.

Furrer, H (2011). Eiszeiten und Klimawandel im Wehntal der vergangenen 200 000 Jahre. Niederweningen: Stiftung Mammutmuseum.

di Iulio, J; Ciuffi, A; Fitzmaurice, K; Kelleher, D; Rotger, M; Fellay, J; Martinez, R; Pulit, S; Furrer, H; Günthard, H F; Battegay, M; Bernasconi, E; Schmid, P; Hirschel, B; Barnes, E; Klenerman, P; Telenti, A; Rauch, A (2011). Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology, 53(5):1446-1454.

Mossdorf, E; Stoeckle, M; Mwaigomole, E G; Chiweka, E; Kibatala, P L; Geubbels, E; Urassa, H; Abdulla, S; Elzi, L; Tanner, M; Furrer, H; Hatz, C; Battegay, M (2011). Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infectious Diseases, 11:98.

Elzi, L; Steffen, I; Furrer, H; Fehr, J; Cavassini, M; Hirschel, B; Hoffmann, M; Bernasconi, E; Bassetti, S; Battegay, M (2011). Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infectious Diseases, 11:319.

Kaufmann, G R; Elzi, L; Weber, R; Furrer, H; Giulieri, S; Vernazza, P; Bernasconi, E; Hirschel, B; Battegay, M (2011). Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS, 25(4):441-451.

Fux, C A; Baumann, S; Furrer, H; Mueller, N J (2011). Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class? AIDS, 25(6):876-878.

Hasse, B; Ledergerber, B; Furrer, H; Battegay, M; Hirschel, B; Cavassini, M; Bertisch, B; Bernasconi, E; Weber, R (2011). Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 53(11):1130-1139.

Ortiz, M; Poloni, E S; Furrer, H; Kovari, H; Martinez, R; Arnedo, M; Elzi, L; Bernasconi, E; Vernazza, P; Hirschel, B; Cavassini, M; Ledergerber, B; Günthard, H F; Telenti, A; Tarr, P E (2011). No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Journal of Infectious Diseases, 203(5):620-624.

Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Medicine, 12(5):279-288.

Glass, T R; Battegay, M; Cavassini, M; De Geest, S; Furrer, H; Vernazza, P L; Hirschel, B; Bernasconi, E; Rickenbach, M; Günthard, H F; Bucher, H C (2010). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(2):197-203.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Gran, J M; Røysland, K; Wolbers, M; Didelez, V; Sterne, J A C; Ledergerber, B; Furrer, H; von Wyl, V; Aalen, O O (2010). A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. Statistics in Medicine, 29(26):2757-2768.

Anselmetti, F S; Drescher-Schneider, R; Furrer, H; Graf, H R; Lowick, S E; Preusser, F; Riedi, M A (2010). A ~180,000 years sedimentation history of a perialpine overdeepened glacial trough (Wehntal, N-Switzerland). Swiss Journal of Geosciences, 103:345-361.

Lubomirov, R; di Iulio, J; Fayet, A; Colombo, S; Martinez, R; Marzolini, C; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Ledergerber, B; Rentsch, K; Descombes, P; Buclin, Thierry; Decosterd, L A; Csajka, C; Telenti, A (2010). ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 20(4):217-230.

Rohrbach, J; Robinson, N; Harcourt, G; Hammond, E; Gaudieri, S; Gorgievski, M; Telenti, A; Keiser, O; Günthard, H F; Hirschel, B; Hoffmann, M; Bernasconi, E; Battegay, M; Furrer, H; Klenerman, P; Rauch, A (2010). Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut, 59(9):1252-1258.

Franceschi, S; Lise, M; Clifford, G M; Rickenbach, M; Levi, F; Maspoli, M; Bouchardy, C; Dehler, S; Jundt, G; Ess, S; Bordoni, A; Konzelmann, I; Frick, H; Dal Maso, L; Elzi, L; Furrer, H; Calmy, A; Cavassini, M; Ledergerber, B; Keiser, O; Swiss HIV Cohort Study (2010). Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. British Journal of Cancer, 103(3):416-422.

Schoeni-Affolter, F; Ledergerber, B; Rickenbach, M; Rudin, C; Günthard, H F; Telenti, A; Furrer, H; Yerly, S; Francioli, P (2010). Cohort profile: the Swiss HIV Cohort study. International Journal of Epidemiology, 39(5):1179-1189.

Rauch, A; Kutalik, Z; Descombes, P; Cai, T; Di Iulio, J; Mueller, T; Bochud, M; Battegay, M; Bernasconi, E; Borovicka, J; Colombo, S; Cerny, A; Dufour, J F; Furrer, H; Günthard, H F; Heim, M; Hirschel, B; Malinverni, R; Moradpour, D; Müllhaupt, B; Witteck, A; Beckmann, J S; Berg, T; Bergmann, S; Negro, F; Telenti, A; Bochud, P Y (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138(4):1338-1338-1345.e7 .

Mossdorf, E; Stoeckle, M; Vincenz, A; Mwaigomole, E G; Chiweka, E; Kibatala, P; Urassa, H; Abdulla, S; Elzi, L; Tanner, M; Furrer, H; Hatz, C; Battegay, M (2010). Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. Tropical Medicine & International Health, 15(5):567-573.

Rotger, M; Gsponer, T; Martinez, R; Taffé, P; Elzi, L; Vernazza, P; Cavassini, M; Bernasconi, E; Hirschel, B; Furrer, H; Weber, R; Ledergerber, B; Egger, M; Telenti, A; Tarr, P E; Swiss HIV Cohort Study (2010). Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals. Clinical Infectious Diseases, 51(9):1090-1098.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Furrer, H; Battegay, M; Vernazza, P L; Bernasconi, E; Rickenbach, M; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2010). Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. Journal of Infectious Diseases, 201(10):1488-1497.

Thurnheer, M C; Weber, R; Toutous-Trellu, L; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Christen, A B; Zwahlen, M; Furrer, H (2010). Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV cohort study. AIDS, 24(12):1907-1916.

Alizon, S; von Wyl, V; Stadler, T; Kouyos, R D; Yerly, S; Hirschel, B; Böni, J; Shah, C; Klimkait, T; Furrer, H; Rauch, A; Vernazza, P L; Bernasconi, E; Battegay, M; Bürgisser, P; Telenti, A; Günthard, H F; Bonhoeffer, S; Swiss HIV Cohort Study (2010). Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathogens, 6(9):e1001123.

Marzolini, C; Elzi, L; Gibbons, S; Weber, R; Fux, C; Furrer, H; Chave, J P; Cavassini, M; Bernasconi, E; Calmy, A; Vernazza, P; Khoo, S; Ledergerber, B; Back, D; Battegay, M (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3):413-423.

Elzi, L; Marzolini, C; Furrer, H; Ledergerber, B; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Weber, R; Battegay, M (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1):57-65.

Veit, O; Niedrig, M; Chapuis-Taillard, C; Cavassini, M; Mossdorf, E; Schmid, P; Bae, H G; Litzba, N; Staub, T; Hatz, C; Furrer, H (2009). Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clinical Infectious Diseases, 48(5):659-66.

Rotger, M; Bayard, C; Taffé, P; Martinez, R; Cavassini, M; Bernasconi, E; Battegay, M; Hirschel, B; Furrer, H; Witteck, A; Weber, R; Ledergerber, B; Telenti, A; Tarr, P E (2009). Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circulation: Cardiovascular Genetics, 2(6):621-628.

Hajdas, I; Michczynski, A; Bonani, G; Wacker, L; Furrer, H (2009). Dating bones near the limit of the radiocarbon dating method: study case mammoth from Niederweningen, ZH Switzerland. Radiocarbon, 51(2):675-680.

Feldmann, M; Furrer, H (2009). Die Saurierspuren am Tödi und ihre geologische Umgebung. In: Kanton Glarus. Obersand 2008 - Sommer der alpinen Artenvielfalt. Glarus: Naturforschende Gesellschaft des Kantons Glarus, 28-37.

Tschochner, M; Chopra, A; Maiden, T M; Ahmad, I F; James, I; Furrer, H; Günthard, H F; Mallal, S; Rauch, A; John, M (2009). Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance. Antiviral Therapy, 14(7):953-964.

Gaudieri, S; Rauch, A; Pfafferott, K; Barnes, E; Cheng, W; McCaughan, G; Shackel, N; Jeffrey, G P; Mollison, L; Baker, R; Furrer, H; Günthard, H F; Freitas, E; Humphreys, I; Klenerman, P; Mallal, S; James, I; Roberts, S; Nolan, D; Lucas, M (2009). Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology, 49(4):1069-1082.

Combescure, C; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV Medicine, 10(8):470-476.

Ballif, M; Ledergerber, B; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Hirschel, B; Furrer, H; Rickenbach, M; Opravil, M; Weber, R (2009). Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE, 4(12):e8275.

di Iulio, J; Fayet, A; Arab-Alameddine, M; Rotger, M; Lubomirov, R; Cavassini, M; Furrer, H; Günthard, H F; Colombo, S; Csajka, C; Eap, C B; Decosterd, L A; Telenti, A (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics, 19(4):300-309.

von Wyl, V; Yerli, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P; Francioli, P; Bonhoeffer, S; Ledergerber, B; Günthard, H (2009). Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clinical Infectious Diseases, 48(7):979-987.

Bucher, H; Furrer, H; Hautmann, M; Klug, C; Sanchez-Villagra, M R (2009). Massenaussterben und Evolution. Zürich: Paläontologisches Institut und Museum, Universität Zürich.

Conen, A; Fehr, J; Glass, T R; Furrer, H; Weber, R; Vernazza, P; Hirschel, B; Cavassini, M; Bernasconi, E; Bucher, H C; Battegay, M (2009). Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 14(3):349-357.

Furrer, H (2009). So kam der Fisch auf den Berg. Chur: Bündner Naturmuseum.

Weber, R; Huber, M; Rickenbach, M; Furrer, H; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Ledergerber, B (2009). Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Medicine, 10(7):407-416.

Keiser, O; Orrell, C; Egger, M; Wood, R; Brinkhof, M W G; Furrer, H; van Cutsem, G; Ledergerber, B; Boulle, A (2008). Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Medicine, 5(7):e148.

Vo, N T T; Ledergerber, B; Keiser, O; Hirschel, B; Furrer, H; Battegay, M; Cavassini, M; Bernasconi, E; Vernazza, P; Weber, R (2008). Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197(12):1685-1694.

Rauch, A; Nolan, D; Furrer, H; McKinnon, E; John, M; Mallal, S; Gaudieri, S; Günthard, H F; Schmid, P; Battegay, M; Hirschel, B; Telenti, A; James, I (2008). HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clinical Infectious Diseases, 46(12):1921-1925.

El Amari, E B; Toutous-Trellu, L; Gayet-Ageron, A; Baumann, M; Cathomas, G; Steffen, I; Erb, P; Mueller, N J; Furrer, H; Cavassini, M; Vernazza, P; Hirsch, H H; Bernasconi, E; Hirschel, B (2008). Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS, 22(9):1019-1028.

HIV Cohort Study, Switzerland; von Wyl, V; Yerly, S; Klimkait, T; Böni, J; Bürgisser, P; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Rickenbach, M; Ledergerber, B; Guenthard, H F (2008). Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical Infectious Diseases, 46:1299-1309.

Berger, S; Schad, T; von Wyl, V; Ehlert, Ulrike; Zellweger, C; Furrer, H; Regli, D; Ledergerber, B; Battegay, M; Weber, R; Gaab, J; Vernazza, P (2008). Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS, 22(6):767-775.

Wunder, D M; Fux, C A; Bersinger, N A; Mueller, N J; Hirschel, B; Cavassini, M; Elzi, L; Schmid, P; Bernasconi, E; Mueller, B; Furrer, H (2008). Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV Medicine, 9(6):427-432.

Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M; Kaufmann, G R (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clinical Infectious Diseases, 47(8):1093-1101.

Wolbers, M; Bucher, H C; Furrer, H; Rickenbach, M; Cavassini, M; Weber, R; Schmid, P; Bernasconi, E; Hirschel, B; Battegay, M (2008). Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Medicine, 9(6):397-405.

Sulser, H; Furrer, H (2008). Dimerelloid rhynchonellide brachiopods in the Lower Jurassic of the Engadine (Canton Graubünden, National Park, Switzerland). Swiss Journal of Geosciences, 101(1):203-222.

Rauch, A; Gaudieri, S; Evison, J; Nolan, D; Cavassini, M; Weber, R; James, I; Furrer, H; Swiss HIV Cohort Study (2008). Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antiviral Therapy, 13(3):455-460.

Furrer, H; Mäder, A (2008). Musée du mammouth de Niederweningen. Niederweningen: Stiftung Mammutmuseum Niederweningen.

Furrer, H; Lozza, H (2008). Neue Funde von Dinosaurierfährten im Schweizerischen Nationalpark. Cratschla, 2008(1):16-21.

Polesel, J; Clifford, G M; Rickenbach, M; Dal Maso, L; Battegay, M; Bouchardy, C; Furrer, H; Hasse, B; Levi, F; Probst-Hensch, N M; Schmid, P; Franceschi, S (2008). Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS, 22(2):301-306.

Rauch, A; Nolan, D; Thurnheer, C; Fux, C; Cavassini, M; Chave, J P; Opravil, M; Phillips, E; Mallal, S; Furrer, H; Swiss HIV Cohort Study (2008). Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antiviral Therapy, 13(8):1019-1028.

Glass, T R; De Geest, S; Hirschel, B; Battegay, M; Furrer, H; Covassini, M; Vernazza, P L; Bernasconi, E; Rickenboch, M; Weber, R; Bucher, H C; Swiss HIV Cohort Study (2008). Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Therapy, 13(1):77-85.

Fux, C; Rauch, A; Simcock, M; Bucher, H; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss HIV Cohort Study (2008). Tenofovir Use Is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 13:1077-1082.

Colombo, S; Rauch, A; Rotger, M; Fellay, J; Martinez, R; Fux, C; Thurnheer, C; Günthard, H F; Goldstein, D B; Furrer, H; Telenti, A (2008). The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. Journal of Infectious Diseases, 198(6):864-867.

Vinn, O; Furrer, H (2008). Tube structure and ultrastructure of serpulids from the Jurassic of France and Switzerland, its evolutionary implications. Neues Jahrbuch für Geologie und Paläontologie, 250(2):129-135.

Furrer, H; Schaltegger, U; Ovtcharova, M; Meister, P (2008). U-Pb zircon age of volcaniclastic layers in Middle Triassic platform carbonates of the Austroalpine Silvretta nappe (Switzerland). Swiss Journal of Geosciences, 101(3):595-603.

von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, P L; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, H F; Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of Internal Medicine, 167(16):1782-1790.

Schüpbach, J; Günthard, H F; Joos, B; Fischer, M B; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. JAIDS Journal of Acquired Immune Deficiency Syndromes, 40(3):250-256.

Hatz, Christoph F R; Beck, B; Blum, J; Funk, M; Furrer, H; Genton, B; Holzer, B; Loutan, L; Markwalder, K; Raeber, P A; Schlagenhauf, Patricia; Siegl, G; Steffen, Robert; Stürchler, D; Wyss, R (2001). Malaria-Chemoprophylaxe 2001. Therapeutische Umschau. Revue thérapeutique, 58(6):347-351.

This list was generated on Mon Jul 24 11:47:23 2017 CEST.